As the non-steroidal anti-inflammatory drugs (NSAIDs) are typically used in the treatment of chronic conditions, the incidence of NSAID-induced enteropathy is increasing. Given the challenges associated with discontinuing NSAIDs, effective preventive and treatment strategies are crucial. We assessed the effect of tegoprazan on NSAID-induced enteropathy. Human epithelial cells (HIEC-6, HT-29, and Caco-2) were treated with indomethacin and tegoprazan. Cell viability, expression levels of tight-junction proteins, levels of proinflammatory cytokines, and apoptosis were assessed by conducting MTT assays, RT-PCR, western blotting, and immunofluorescence staining, respectively. Tegoprazan significantly ameliorated the inhibition of cell proliferation induced by indomethacin. Tegoprazan also mitigated the suppression of occludin and ZO-1 expression by indomethacin, thereby restoring intestinal permeability. Additionally, tegoprazan reversed the indomethacin-induced elevation of the levels of proinflammatory cytokines and the rate of apoptosis of small intestinal epithelial cells. Our findings indicate that tegoprazan exerts a protective effect against NSAID-induced injury to small intestinal epithelial cells. The effect involves enhancement of the expression levels of tight junction proteins and the suppression of inflammation and apoptosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543827 | PMC |
| http://dx.doi.org/10.1038/s41598-024-78581-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medications for the management of chronic pain; however, they are associated with gastrointestinal (GI) adverse events. Although many mechanisms have been suggested, NSAID-induced enteropathy has been thought to be primarily due to inhibition of both cyclooxygenases (COX) -1 and -2, which results in suppression of prostaglandin synthesis. Here we report that concomitant postnatal deletion of and over 10 months failed to cause intestinal injury in mice unless they were treated with naproxen or its structural analog, phenylpropionic acid, which is not a COX inhibitor.
View Article and Find Full Text PDFGardenia jasminoides fruit extract alleviates non-steroidal anti-inflammatory drug-induced gastropathy in rats.
BMC Complement Med Ther
November 2024
Center of Excellence in Alternative and Complementary Medicine for Gastrointestinal and Liver Diseases, Department of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Background: NSAID-induced gastropathy is a health burden that requires effective intervention. Among various prevention options, Gardenia jasminoides fruit extract (GJE) has demonstrated gastroprotective effects through anti-inflammatory pathways with a wide safety margin. However, the detailed molecular mechanisms of GJE regarding mucoprotective and anti-inflammatory effects remained to be explored.
View Article and Find Full Text PDFEffect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy.
Sci Rep
November 2024
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.
As the non-steroidal anti-inflammatory drugs (NSAIDs) are typically used in the treatment of chronic conditions, the incidence of NSAID-induced enteropathy is increasing. Given the challenges associated with discontinuing NSAIDs, effective preventive and treatment strategies are crucial. We assessed the effect of tegoprazan on NSAID-induced enteropathy.
View Article and Find Full Text PDFDiaphragm Disease of the Terminal Ileum: The Great Imitator.
Eur J Case Rep Intern Med
September 2024
Department of Gastroenterology, University of Balamand, Beirut, Lebanon.
Article Synopsis
- - Non-steroidal anti-inflammatory drugs (NSAIDs) can cause serious intestinal issues, including diaphragm disease, which leads to thick, narrow strictures and potential bowel obstruction.
- - Diaphragm disease is often difficult to diagnose and can be treated conservatively by stopping NSAID use, as demonstrated in a case of a 59-year-old woman who experienced abdominal pain.
- - With the increasing use of NSAIDs, healthcare providers should consider diaphragm disease when diagnosing patients with vague abdominal pain or obstruction symptoms related to chronic NSAID use.
NSAID-induced Gastric Ulcer Disease: A Deleterious Connection.
Discov Med
September 2024
Department of Internal Medicine, Fazaia Ruth Pfau Medical College, 74350 Karachi, Pakistan.
Article Synopsis
- Gastric ulcers caused by long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) are a rising public health concern, primarily linked to their role in developing peptic ulcers.
- The review highlights various risk factors associated with NSAID use, including anticoagulant therapy, and discusses the clinical signs, symptoms, diagnosis, prevention, and treatment of these ulcers.
- Recommendations for prevention include using selective COX-2 inhibitors instead of traditional NSAIDs and minimizing dosages for patients with other health conditions to reduce ulcer risk.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!